About us
RNT consulting offers support in the development and commercialization of radiopharmaceuticals. We have unique expertise in alpha and beta emitting therapeutics and novel PET diagnostic agents.
RNT consulting’s approach is customized for each situation to determine the best strategy to meet the client’s goals. We have extensive expertise throughout the product lifecycle from pre-clincal development to commercialization.
Our experience
RNT consulting has unique experience from over 15 years of radiopharmaceutical development, including development and launch of the first-in-class alpha emitting pharmaceutical radium-223 dichloride/Xofigo and working for a range of clients worldwide developing a range of theranostic products.
Copyright © 2019 All Rights Reserved